Drug intelligence / Profile preview

IL2104

Development stage: Preclinical
Lead developer: Idience
Modality: Small Molecules

Overview

IL2104 is a preclinical-stage small molecule inhibitor that selectively targets poly(ADP-ribose) polymerase 1 (PARP1). Developed by iLeadBMS, a spin-off biotech subsidiary of Ildong Pharmaceutical, IL2104 is designed to treat various solid tumors. By selectively inhibiting PARP1 while sparing PARP2, the compound aims to achieve synthetic lethality in cancer cells with DNA repair deficiencies while minimizing the hematological toxicities often associated with dual PARP1/2 inhibitors.

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on IL2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL2104.

Explore the full profile